Adapalene Gel 0.3% in the Treatment of Atrophic Acne Scars

Acne Scars Clinical Trial

Official title:

Efficacy and Safety of Adapalene Gel 0.3% in the Treatment of Atrophic Acne Scars. A Pilot Study.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01213199
• Other study ID #: RD.03.SPR.29088
• Status: Completed
• Phase: Phase 2
• Start date: March 2011
• Est. completion date: September 2012

Study information

• Verified date: March 2015
• Source: Galderma R&D
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess the efficacy and safety of Adapalene Gel 0.3% in the treatment of atrophic acne scars.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: September 2012
• Est. primary completion date: April 2012
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

• Male or female subjects of any race, aged 18 to 50 years inclusive

• Subjects with a past history of acne and with moderate to severe facial atrophic acne scars

Exclusion Criteria:

• Subjects with active inflammatory acne lesions

• Subjects with hypertrophic acne scars

Related Conditions & MeSH terms

• Acne Scars
• Acne Vulgaris
• Atrophy
• Cicatrix

Intervention

Drug:
• Adapalene
Adapalene Gel 0.3%

Locations

Country	Name	City	State
United States	Manisha PATEL	Baltimore	Maryland

Sponsors (1)

Lead Sponsor	Collaborator
Galderma R&D

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Global Scarring Severity	Grade Level: Macular disease; Mild disease; Moderate disease; Severe disease	Week 24

External Links

•   Related Info